Skip to content
Colorectal Cancer Clinical Trials

Nashville, Tennessee

Colorectal cancer clinical trials in Nashville, TN

78 colorectal cancer studies are recruiting participants at sites in Nashville as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Nashville at a glance

  • 78 studies are recruiting at a site in Nashville.
  • By phase: Phase 1 (29), Phase 1/2 (23), Phase 2 (10), Phase 2/3 (2), Phase 3 (7), Phase 4 (1), No phase (1), Observational (5). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (66), university, hospital or other (9), government (3).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Nashville

Basic details from each study's public record (the 30 most recently updated of 78). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05863195 · updated
  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    SCRI Oncology Partners · Tennessee Oncology, Pllc
    Registry record
    NCT06324357 · updated
  3. A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07213609 · updated
  4. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vividion Therapeutics, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06004245 · updated
  5. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Tennessee Oncology
    Registry record
    NCT06270706 · updated
  6. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Sarah Cannon Research Institute Oncology Partners
    Registry record
    NCT07659795 · updated
  7. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
    Registry record
    NCT04557449 · updated
  8. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07020221 · updated
  9. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07503808 · updated
  10. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    SCRI Oncology Partners
    Registry record
    NCT04929223 · updated
  11. Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Riboscience, LLC.
    Study site
    SCRI Oncology LLC
    Registry record
    NCT06824064 · updated
  12. A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07549412 · updated
  13. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05174169 · updated
  14. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Jazz Pharmaceuticals
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06695845 · updated
  15. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06760819 · updated
  16. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Tennessee Oncology
    Registry record
    NCT07397338 · updated
  17. A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Vanderbilt Ingram Cancer Center
    Registry record
    NCT05379595 · updated
  18. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05673148 · updated
  19. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06662786 · updated
  20. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    SCRI Oncology Partners · Tennessee Oncology · Vanderbilt University Medical Center
    Registry record
    NCT06750094 · updated
  21. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07542704 · updated
  22. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Sarah Cannon Research Institute Oncology Partners
    Registry record
    NCT07584226 · updated
  23. LYL273 for Patients With Relapsed or Refractory mCRC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    SCRI Oncology Partners and Tristar Centennial Hospital
    Registry record
    NCT05319314 · updated
  24. Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Vanderbilt Breast Center at One Hundred Oaks · Vanderbilt University/Ingram Cancer Center
    Registry record
    NCT05803382 · updated
  25. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    A2 Biotherapeutics Inc.
    Study site
    Vanderbilt University Medical Center
    Registry record
    NCT04981119 · updated
  26. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    SCRI Oncology Partners
    Registry record
    NCT06330064 · updated
  27. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  28. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    SCRI Oncology Partners
    Registry record
    NCT07221357 · updated
  29. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study sites
    SCRI Oncology Partners · Vanderbilt Medical Center
    Registry record
    NCT04657068 · updated
  30. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ModeX Therapeutics, An OPKO Health Company
    Study site
    Sarah Cannon Research Institute
    Registry record
    NCT06239194 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Nashville, TN on ClinicalTrials.gov.

Ask about studies near Nashville

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call